HPTN 083-01

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Males – A sub-study of HPTN 083

Study Summary
083-01 Logo


Study Documents - Study Details - Key Study Personnel - Study Sites - Publications


What is HPTN 083-01?

HPTN 083-01 is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (pre-exposure prophylaxis) is safe and acceptable for adolescent males [assigned male at birth – including men who have sex with men (MSM), transgender women (TGW), and gender nonconforming people].

Who is participating in HPTN 083-01?

This study will be enrolling about 50 adolescent males (assigned male at birth – including MSM, TGW, and gender nonconforming people) under the age of 18 at sites in Boston, Chicago, and Memphis. 

Why is HPTN 083-01 important?

Adolescents and young adults make up a large number of new HIV infections worldwide. Although taking a daily pill for PrEP works to protect people from HIV, having to take a daily pill has proven to be difficult for some people. Long-acting injectable PrEP has the potential to protect people from HIV without having to take a daily pill.

What will happen during HPTN 083-01?

Participants will move through the study in 3 steps:

Step 1: Participants will take one CAB pill every day for five weeks

Step 2: Participants will receive a total of 5 CAB injections over 6 months

Step 3: Participants will come to the clinic for study visits quarterly and receive Truvada for PrEP for about one year.

083-01 schema



Study Documents

Version 3.0

Version 2.0

Version 1.0

➤ HPTN 083-01 SSP

(Click to Expand)
Previous versions of the SSP sections are available upon request

Other tools



Engaging Adolescent Sexual and Gender Minority Persons in Long-Acting HIV Pre-Exposure Prophylaxis in the U.S.

Douglas Krakower | International Workshop on HIV & Pediatrics 2022 | 27 July 2022


More Study Documents

You must request access to private documents (i.e. call summaries) from the study team. Please email Gabriela Salinas-Jimenez at GSalinas-Jimenez@fhi360.org for access to these documents.

Study Details

Protocol Status: Closed to Follow Up
Study Purpose:

To establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.

Study Design:

A Phase IIB single arm, open label safety, tolerability, and acceptability study

Study Population:

Sexually-active, healthy male (assigned at birth) adolescents aged below 18 years

Study Size:

Approximately 50

Study Duration:

Participant recruitment will take approximately 12 months. Oral study product will be administered for 5 weeks, followed by 29 weeks on injectable product, then quarterly visits for 48 weeks after final injection. All participants who have received at least one injection will be followed for 48 weeks after their last injection. Waning levels of cabotegravir (the PK tail) will be covered with locally sourced oral TDF/FTC for daily use for 48 weeks. Total study duration per participant will be approximately 21 months.

Treatment Regimen:

Step 1 – oral cabotegravir (30mg tablet); Step 2 – 3 mL (600 mg) intramuscular (IM) injection; Step 3 – Tenofovir/Emtricitabine (Trade name: TDF/FTC, Truvada®) (300mg/200mg tablet)

Primary Objectives:

• To evaluate the safety, tolerability and acceptability of CAB LA in healthy HIV-uninfected male adolescents aged below 18 years

Secondary Objectives:

• To examine adherence to and timeliness of injections over time among adolescent participants who are provided CAB LA and information regarding its safety and unknown efficacy.
• To examine patterns of sexual risk behavior over time among adolescent participants who are provided CAB LA and information regarding its safety and unknown efficacy.
• To evaluate the safety of CAB LA for 48 weeks of follow-up after final injection.
• To characterize the pharmacokinetics of CAB LA.

Key Study Personnel

Adeola Adeyeye, DAIDS Medical Officer
erica hamilton, LOC Clinical Research Manager
Sybil Hosek, Protocol Chair
Bill Kapogiannis, NICHD Medical Officer
Scott Rose, LOC Clinical Research Manager
Lynda Stranix-Chibanda, Protocol Co-Chair